The Trump administration has initiated a Section 301 trade investigation into Germany, alleging that its pharmaceutical spending policies harm US drugmakers and patients by artificially suppressing drug prices. This move marks the first time the US has used a Section 301 investigation to target a country's drug pricing policies. The investigation could lead to tariffs on German goods if negotiations fail to resolve the dispute.
US officials argue that Germany's stringent price controls force American patients to subsidize drug development, as US consumers pay significantly more for pharmaceuticals. They claim that Germany's low prices undermine the profitability needed for research and development. The US Trade Representative described Germany's actions as an unfair trade practice under Section 301 of the Trade Act of 1974.
Germany's health ministry has defended its policies, stating that they are designed to ensure affordable access to medicines for its citizens and are in line with European Union law. The investigation comes as Germany considers new legislation to further control healthcare costs, which could exacerbate tensions with the US. This action is part of a broader Trump administration effort to pressure European nations to pay more for drugs, following similar pressure on the UK.
